BACKGROUND: Luspatercept, an inhibitor of the transforming growth factor beta (TGF-β) pathway, is a novel treatment for anemic patients with lower-risk myelodysplastic syndromes (MDS) with transfusion dependence (TD) who do not respond to erythropoiesis-stimulating agents (ESA) therapy or are not suitable candidates for this treatment. We present real-world experience with luspatercept therapy from two hematology centers in the Czech Republic. METHODS: By January 2024, 54 MDS patients (33 men, 21 women) with a median age of 74 years (range, 55-95) were treated with luspatercept ± ESA at two Charles University hematology centers in Prague and Hradec Králové. According to the WHO 2016 classification, the cohort included 32 MDS-RS-MLD, seven MDS-MLD, two patients with 5q- + ring sideroblasts (RS), 12 RARS-T, and 1 patient with CMML-0 + RS. SF3B1 mutation data were available for 45 patients. All patients were in the IPSS-R and IPSS-M lower-risk groups (except four IPSS-M high). The median follow-up was 17 months (range, 1-54). All patients were transfusion-dependent. Thirty-five (64.8%) patients had a high transfusion burden (HTB) with ≥ 4 transfusion units (TU)/8 weeks, and 19 (35.2%) had a low transfusion burden (LTB) (< 4 TU/8 weeks). The median time between diagnosis and initiation of luspatercept was 27 months (range, 4-156). ESA were used prior to luspatercept in 45 patients, and luspatercept was used as first-line treatment in nine patients. Thirty-one (61%) patients were treated simultaneously with ESA. RESULTS: Only patients who received luspatercept for ≥ 8 weeks (51 patients) were assessed. We evaluated the achievement of transfusion independence (TI) lasting 8, 12, 16, and 24 weeks. Thirty-two (62.7%) patients achieved TI for ≥ 8 weeks, 31 (60.7%) for ≥ 12 weeks, 29 (56.8%) for ≥ 16 weeks, and 25 (49%) for ≥ 24 weeks. Hematologic improvement (HI) without TI was achieved in six patients (11.7%). Overall, HI + TI was achieved in 38 patients (74.5%). Epoetin alfa was used simultaneously in 31 patients (60.7%). In 21 (55.2%) of all responding patients, concomitant therapy with epoetin alfa led to an improved response, with 16 reaching TI. Thirteen (25.5%) patients were nonresponders. Eight (21%) patients experienced therapy failure and became transfusion-dependent again. Optimal response required a gradual increase in the luspatercept dose to 1.75 mg/kg in up to 35 patients, with 23 responders (TI + HI). Response rates varied by transfusion burden: 79% in LTB and 50% in HTB reached TI. Of RS+ patients, 70% reached TI, while only one out of five RS- patients achieved TI. Among 39 SF3B1-positive patients, 61.6% achieved TI. In the low and very low IPSS-M groups, 86% of patients responded (TI + HI), compared to 62% in the moderate-low group. Luspatercept was well-tolerated, with no adverse events higher than grade II toxicity. CONCLUSION: We have demonstrated in real-world clinical practice that luspatercept is a very effective agent, even in an unselected, pretreated, significantly TD MDS population. The effect was particularly high in the IPSS-M low and very low groups. We believe that the relatively high response rate in our patients was influenced by the frequent use of a higher dose (1.75 mg/kg) and especially by adding ESA to luspatercept in poorly responding patients.

1st Department of Medicine Hematology General University Hospital and 1st Faculty of Medicine Charles University Prague Czechia

4th Department of Internal Medicine Hematology Charles University Hospital Hradec Kralove Czechia

BIOCEV 1st Faculty of Medicine Charles University Prague Czechia

Center of Oncocytogenomics Institute of Clinical Biochemistry and Laboratory Diagnostics General University Hospital and 1st Faculty of Medicine Charles University Prague Czechia

University College of London London United Kingdom

Zobrazit více v PubMed

Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F, et al. . Revised international prognostic scoring system for myelodysplastic syndromes. Blood. (2012) 120:2454–65. doi: 10.1182/blood-2012-03-420489 PubMed DOI PMC

Bernard E, Tuechler H, Greenberg PL, Hasserjian RP, Arango Ossa JE, Nannya Y, et al. . Molecular international prognosis scoring system for myelodysplastic syndromes. NEJM evid. (2022) 1(7). doi: 10.1056/EVIDoa2200008 PubMed DOI

Monserrat AS, Pomares H, Alonso E, Grau J, Galiano M, Encuentra M, et al. . Impact of red blood cell transfusion burden status in patients with lower-risk MDS. Blood. (2019) 134:3031.

Neukirchen J, Fox F, Kündgen A, Nachtkamp K, Strupp C, Haas R, et al. . Improved survival in MDS patients receiving iron chelation therapy - A matched pair analysis of 188 patients from the düsseldorf MDS registry. Leuk. Res. (2012) 36:1067–70. doi: 10.1016/j.leukres.2012.04.006 PubMed DOI

Fenaux P, Santini V, Platzbecker U, Aloe Spiriti MA, Giagounidis A, Schlag R, et al. . A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-α in anemic patients with low-risk MDS. Leukemia. (2018) 32:2648–58. doi: 10.1038/s41375-018-0118-9 PubMed DOI PMC

Platzbecker U, Symeonidis A, Oliva EN, Goede JS, Delforge M, Mayer J, et al. . ARCADE (20090160): a phase 3 randomized placebo-controlled double-blind trial of darbepoetin alfa in the treatment of anemia in patients with low and intermediate-1 risk myelodysplatic syndromes (MDS). Haematologica. (2016) 101:15. doi: 10.1182/blood.V128.22.2010.2010 DOI

Kubasch AS, Fenaux P, Platzbecker U. Development of luspatercept to treat ineffective erythropoiesis. Blood Adv. (2021) 5:1565–75. doi: 10.1182/bloodadvances.2020002177 PubMed DOI PMC

Platzbecker U, Germing U, Götze KS, Kiewe P, Mayer K, Chromik J, et al. . Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study. Lancet Oncol. (2017) 18:1338–47. doi: 10.1016/S1470-2045(17)30615-0 PubMed DOI

Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, et al. . Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. (2006) 108:419–25. doi: 10.1182/blood-2005-10-4149 PubMed DOI

Fenaux P, Platzbecker U, Mufti GJ, Garcia-Manero G, Buckstein R, Santini V, et al. . Luspatercept in patients with lower-risk myelodysplastic syndromes. N Engl J Med. (2020) 382:140–51. PubMed

Garcia-Manero G, Mufti GJ, Fenaux P, Buckstein R, Santini V, Diez-Campelo M, et al. . Neutrophil and platelet increases with luspatercept in lower-risk MDS: secondary endpoints from the MEDALIST trial. Blood. (2022) 139:624–9. doi: 10.1182/blood.2021012589 PubMed DOI PMC

Platzbecker U, Della Porta MG, Santini V, Zeidan AM, Komrokji RS, Shortt J, et al. . Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial. Lancet. (2023) 402:373–85. doi: 10.1016/S0140-6736(23)00874-7 PubMed DOI

Zermati Y, Fichelson S, Valensi F, Freyssinier JM, Rouyer-Fessard P, Cramer E, et al. . Transforming growth factor inhibits erythropoiesis by blocking proliferation and accelerating differentiation of erythroid progenitors. Exp Hematol. (2000) 28:885–94. doi: 10.1016/S0301-472X(00)00488-4 PubMed DOI

Verma A, Suragani RNVS, Aluri S, Shah N, Bhagat TD, Alexander MJ, et al. . Biological basis for efficacy of activin receptor ligand traps in myelodysplastic syndromes. J Clin Invest. (2020) 130:582–9. doi: 10.1172/JCI133678 PubMed DOI PMC

Grover A, Mancini E, Moore S, Mead AJ, Atkinson D, Rasmussen KD, et al. . Erythropoietin guides multipotent hematopoietic progenitor cells toward an erythroid fate. J Exp Med. (2014) 211:181–8. doi: 10.1084/jem.20131189 PubMed DOI PMC

Malik J, Kim AR, Tyre KA, Cherukuri AR, Palis J. Erythropoietin critically regulates the terminal maturation of murine and human primitive erythroblasts. Haematologica. (2013) 98:1778–87. doi: 10.3324/haematol.2013.087361 PubMed DOI PMC

Tusi BK, Wolock SL, Weinreb C, Hwang Y, Hidalgo D, Zilionis R, et al. . Population snapshots predict early haematopoietic and erythroid hierarchies. Nature. (2018) 555:54–60. doi: 10.1038/nature25741 PubMed DOI PMC